Clinical Trials on Melanoma, Skin

Total 52076 results

Ultimovacs ASA

Completed

UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

Malignant Melanoma

United States, Belgium, United Kingdom, Norway
Novartis

Completed

Patient Characteristics, Treatment Patterns, and Healthcare Resource Utilization of Metastatic Melanoma Patients

Metastatic Melanoma

Switzerland
National Cancer Institute (NCI)

Active, not recruiting

Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...

Skin Cancer | Metastatic Melanoma

United States
National Cancer Institute (NCI)

Completed

Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma

Skin Cancer | Metastatic Melanoma

United States
National Cancer Institute (NCI)

Completed

Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M...

Melanoma | Skin Cancer | Metastatic Melanoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain

Metastatic Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Malignant Neoplasm in the Brain

United States
Immunocore Ltd

Recruiting

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) (PRISM-MEL-301)

Advanced Melanoma

United States, Australia
M.D. Anderson Cancer Center

Recruiting

PRISM: Pre-Operative Radiotherapy and Immunotherapy for Sinonasal Melanoma

Sinonasal Melanoma

United States
NYU Langone Health

Recruiting

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

Melanoma | Unresectable Melanoma

United States
Dana-Farber Cancer Institute
Celldex Therapeutics

Recruiting

NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma

Melanoma | Metastatic Melanoma

United States
Uppsala University

Recruiting

A Randomized Trial to Assess the Role of Imaging During Follow up After Radical Surgery of High Risk Melanoma (TRIM)

Malignant Melanoma

Sweden
Fondazione Melanoma Onlus
Clinical Research Technology S.r.l.

Completed

Sequential Combo Immuno and Target Therapy (SECOMBIT) Study (SECOMBIT)

Metastatic Melanoma

Italy, Germany, Spain, Greece, Austria, France, Poland, Sweden, Switzerland, United Kingdom
Pfizer

Completed

A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial Settings

Metastatic Melanoma

United States
Genentech, Inc.
BioNTech SE

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma. (IMCODE001)

Advanced Melanoma

United States, Spain, Belgium, Australia, Germany, United Kingdom
University Hospital, Basel, Switzerland
GMP network of Basel

Completed

Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for Melanoma (BaseTIL)

Advanced Melanoma

Switzerland
Elios Therapeutics, LLC
LumaBridge

Completed

Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.

Metastatic Melanoma

United States
Castle Biosciences Incorporated

Terminated

Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous Melanoma and Associated Patient Outcomes (EXPAND)

Cutaneous Melanoma

United States
National Cancer Institute (NCI)

Terminated

Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma

Skin Cancer | Metastatic Melanoma

United States
Oxford University Hospitals NHS Trust
University of Southampton

Recruiting

MoleGazer Development Feasibility Study

Melanoma (Skin) | Moles Multiple Benign

United Kingdom
Institute of Cancer Research, United Kingdom
Royal Marsden NHS Foundation Trust

Completed

A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread (NICAM)

Mucosal Lentiginous Melanoma | Acral Lentiginous Malignant Melanoma

United Kingdom
University of Texas Southwestern Medical Center

Recruiting

Identification of Metabolic Phenotypes Associated With Melanoma Metastasis

Melanoma (Skin)

United States
M.D. Anderson Cancer Center

Recruiting

Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors

Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIA Cutaneous Melanoma... and other conditions

United States
University of Chicago
National Cancer Institute (NCI)

Completed

Detection of Melanoma Markers in Lymph Nodes or Peripheral Blood of Patients With Melanoma

Melanoma (Skin)

United States
Regina Elena Cancer Institute
Istituti Fisioterapici Ospitalieri

Recruiting

Biobanking and New Biomolecular Metrics (Melamoma4p)

Melanoma (Skin) | Liquid Biopsy

Italy
Herlev Hospital

Enrolling by invitation

Dermoscopy Augmented Histology Trial, Consensus Agreement Diagnosis Made by Dermatopathology Experts

Melanoma (Skin) | Pigmented Lesions

Denmark
Mayo Clinic
National Cancer Institute (NCI)

Completed

Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy

Stage IV Skin Melanoma

United States
Grupo Español Multidisciplinar de Melanoma

Completed

Translational Study for BRAFV600 Serum and Plasma Determination in Patients With BRAFV600 Metastatic Melanoma (BRAFV600)

Stage IV Skin Melanoma

Spain
National Cancer Institute (NCI)

Terminated

Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | BRAF V600E Mutation Present | BRAF V600K Mutation Present | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
Memorial Sloan Kettering Cancer Center

Recruiting

CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma

Melanoma | Melanoma Stage III

United States
University Hospital, Essen

Active, not recruiting

Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma (NivoMela)

Malignant Melanoma Stage II

Germany
Instil Bio

Terminated

ITIL-168 in Advanced Melanoma (DELTA-1)

Advanced Cutaneous Melanoma

United States, Canada, United Kingdom
Dana-Farber Cancer Institute
Novartis

Completed

Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma (BUS255)

Mucosal Melanoma | Acral/Lentiginous Melanoma | Chronically Sun Damaged Melanomas

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma

Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIA Cutaneous Melanoma...

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Bone Loss in Melanoma Survivors Receiving Immunotherapy

Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIA Cutaneous Melanoma... and other conditions

United States
Sun Yat-sen University

Completed

Characteristics and Tumor Staging Proposal for Primary Malignant Melanoma of the Esophagus

Primary Malignant Melanoma of the Esophagus

China
University of Alabama at Birmingham
Amgen

Completed

Can We Miss Pigmented Lesions in Psoriasis Patients?

Melanoma | Psoriasis | Non-melanoma Skin Cancer

United States
Novartis Pharmaceuticals

Recruiting

A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas

Metastatic Uveal Melanoma

United States, Australia, France, Netherlands, Switzerland, Germany, Spain
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma

Recurrent Melanoma | Stage IV Melanoma | Stage III Melanoma
Vical

Completed

Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma

Recurrent Melanoma | Stage IV Melanoma | Stage III Melanoma

United States
Vical

Completed

Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma

Recurrent Melanoma | Stage IV Melanoma | Stage III Melanoma

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement

Melanoma of Unknown Primary | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Recurrent Cutaneous Melanoma | Metastatic Malignant Neoplasm in Lymph Node

United States
Beijing Scitech-Mq Pharmaceuticals Limited

Recruiting

A Study of ST-1898 for Unresectable or Metastatic Melanoma

Unresectable or Metastatic Melanoma

China
M.D. Anderson Cancer Center

Recruiting

Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients

ICB-refractory Melanoma

United States
Azienda Ospedaliero-Universitaria di Modena

Completed

Advanced Non-invasive Diagnostics for Early Cutaneous Tumor Diagnosis, Clinical-therapeutic and Economic Management (NET-DAM)

Cutaneous Melanoma
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

Metastatic Uveal Melanoma | Stage IV Uveal Melanoma AJCC v7

United States
Immunocore Ltd

Recruiting

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

Advanced Melanoma

United States, Australia, Spain, Italy, Germany, Belgium, United Kingdom, Poland, France, Austria, Switzerland
Massachusetts General Hospital
Massachusetts Institute of Technology

Recruiting

PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma

Metastatic Melanoma

United States
Yana Najjar
Merck Sharp & Dohme LLC

Recruiting

A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma

Advanced Melanoma

United States
Philogen S.p.A.

Recruiting

Neoadjuvant L19IL2/L19TNF- Pivotal Study (Pivotal)

Malignant Melanoma

Italy, France, Germany, Poland
Parker Institute for Cancer Immunotherapy
Seres Therapeutics, Inc.

Completed

Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention (MCGRAW)

Metastatic Melanoma

United States

Clinical Trials on Melanoma, Skin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Austria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations